Used in research and therapeutic development targeting inflammatory and autoimmune diseases, this antibody specifically binds to TNFSF12 (TWEAK), a cytokine involved in inflammation, cell survival, and tissue remodeling. By neutralizing TWEAK activity, it helps modulate signaling pathways associated with chronic inflammation, fibrosis, and tumor progression. It is particularly valuable in studies related to rheumatoid arthritis, lupus nephritis, and certain cancers, where TWEAK-mediated signaling contributes to disease pathology. The antibody serves as a reference tool for evaluating the efficacy and mechanism of anti-TWEAK therapies and supports the development of biologics aimed at blocking TWEAK/Fn14 interactions.